Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Head.
Hello. Thank you everyone. Taking some time off. Hopefully you are enjoying some vacation time while listening to Asker Group's Q2 report. We are happy and proud to present 24% adjusted EBITA growth, of which 6% was organic for this quarter. We are also happy to see a 10% EBITDA margin for this quarter, so that is good if we take a few highlights one by one: net sales were 4.7 billion this quarter, up 18%, out of which 5% was organic. The adjusted EBITDA was 471 million, up 24%, as I mentioned, with 6% organic growth, and the margin was 10%, which was up half a percentage point from last year. We have a robust cash flow and efficient working capital. So our most important KPI, R/RK or EBITDA over net working capital, was 69%. We work hard, as you know, with ESG and sustainability and were rated MSCI Triple A for the first time. So that is also something we are happy to see. And it helps us win tenders, especially in Northern Europe. And it actually supports our business in a very good way. In terms of acquisitions. We had one new acquisition in Ireland in July, and we have passed 50% of our annual targets in acquisitions, which we will touch upon a little bit later. As we usually say, the best way to follow us as a company is on a rolling 12-month basis. And we have a target of delivering more than 15% of EBITDA growth. It is now 21%. It is now at 21% overall. Overall, ROCE is 69%, and our margin on the rolling 12-month basis is now steadily growing to 9.8%. Our leverage, as you know, is important to keep under two and a half times. And we are now at 2.37 times. So that gives us some headroom upwards. We usually show these pictures as well. We have had many, many years of good growth in this company. And we have hopefully many years to come both organically as well as via M&A. And now we're adding another bar to the right in this picture, also way above the 50% growth, which is good to see. I hand over to Thomas.
Great. Thanks, Johan. Let's go into some of the numbers in a little bit more detail. But very much supporting the message that you gave there, continued solid growth across the group. So net sales in Q2 were up 18%, 5% of that organic, as Johan mentioned, with zero FX effect in this particular quarter, and adjusted EBITA, again, as Johan mentioned, was up 24%, of which 6% was organic. And again, no FX effect on the EBITA line, with margins at 10%. I think for us, what is pleasing to see is that we do see growth coming from all parts of the group, all regions, and the vast majority of companies performing very nicely. The newly acquired companies are coming in well, supporting the growth of the group as a whole. This is also helping to drive the margin expansion that we see when we look at the overall figures. If we look on the right-hand side of this page, we see the half-year picture, January to June, also very much in line with what we said at Q1. As you will remember, we had a solid Q1. We backed that up now with another good, solid Q2 report. And so we see the half-year effect of that 7% organic EBITA growth and 23% total EBITA growth so far this year. If I move to the business areas one by one, let's start with Business Area North. Also a good quarter performing nicely with the organic growth coming through. Net sales up 13%, EBITDA up 10%. It is important for us to see that we are able to maintain those good margins in Region North above 13% on an LTM basis. Worth also noting, we've talked about this before, the new distribution center in Gothenburg progressing well in line with our plans. Actually, we have started to drive some early-stage operational activities through that system, which is going nicely, and we will continue to ramp that up through the second half of the year. On the right-hand side, the half-year figures are again very much in line with Q1 and Q2 stability and solid performance; we see adjusted EBITDA growth of 8% and net sales growing at 10%. Turning to business area West, another strong quarter in West, with adjusted EBITA up 32%. It is nice to see that the margin is also rising as we hope and expect. Now up to 9.6% in Q2 and again, steady performance across the business area, very much in line with what we've been reporting from West in recent quarters. Also worth noting that the larger acquisitions that we have done in West in recent times are also delivering very strongly and helping to support those scale business benefits, and the growing home care business is also driving that scale benefit across the region as well. And then our third region, Business Area Central, is a very similar story to the one that we've presented for the other two regions, continuing the strength in the results, with positive margin development and M&A contributing strongly. So net sales were up 33% in the quarter, and adjusted EBITA was up 56%. And the margin again rising nicely in quarter 2 to 9.6%. A very similar message to the one I have given for other regions in the group as a whole, with recent acquisitions contributing strongly to the overall region and continuing the trends that we have seen in recent quarters. At the half-year, adjusted EBITA growth in Central is now running at 52%, with net sales growth of 29%. A brief mention of R/RK, EBITDA over net working capital. We always include this, our key internal metric, as Johan mentioned, to make sure that we're focusing on that right balance between profit and also efficiency in terms of how we deploy our working capital. So, it is good to see that we are maintaining strong performance on this metric. And then, cash flow. I spent a little bit longer on cash flow in Q1. I will do the same again now, given that we had some significant one-off cash outflows in Q2. The good thing, from our perspective, is that they came in exactly as forecast, which continues to show that we have good visibility of our cash flow and the availability of that cash flow, which is so important to driving our M&A agenda and enabling us to use that great pipeline that we have going forward. So, the adjusted cash flow from operating activities was 330 million in Q2. Good, solid performance from the group. CAPEX. We continue to invest. Our biggest investment at the moment is the new warehouse in Gothenburg that I mentioned, very much in line with the plan. Approximately 75 million remains to be spent on CAPEX in that facility during the remainder of 2026. During the remainder of 2026. The significant one-off cash flows that I mentioned were both forecasted and anticipated. Earnouts of 463 million SEK were paid for company earnouts for deals that came to the end of their earnout period in December 2025. And of course, the dividend is the first time we have paid that out. Cash conversion. I just add this as a note. It is not a KPI that we lift to the very highest level, but it is one that we actually monitor very, very closely internally. So it is good to see that it is running at a healthy level above 80%. And then a final note on cash flow, as we continue to look forward. We continue to want to make sure that we have good visibility of that. It is worth once again reflecting that the large, significant one-off cash outflows we had in Q2 this year were something of an exception. When we look forward to 2027, the earn-out payments are currently forecasted at a much lower level of only 150 million SEK. And the final slide from me, just a word or two on leverage. Naturally. And again, as anticipated, the leverage was marginally and temporarily elevated because of those large cash outflows that I talked about, but still at a level that very much ensures that we can continue to have the capacity to drive the M&A agenda. 2.37 according to our external target definition. But also, as we talked about a little bit at Q1, there are other ways of thinking about leverage. So I also continue to present the alternative leverage ratio that we look at, which is really equivalent to our bank leverage covenant, which means that we include all of the earnouts and outstanding M&A payments that are due in the next 12 months. And we also include the 12-month pro forma EBITDA from the acquisitions that we have done. And that gives a figure of 2.43. With that said, I think I hand it back to Johan.
Thank you. Thomas. Okay, so let's look into the M&A part of our business. We have done four acquisitions year to date, and two of them are a little bit on the upper side of our range, 300 and 350 million SEK. So we have the last one, Murray Surgical, was completed in July, adding some 73 million SEK in annual sales. You might also have noticed that we discontinued an acquisition in Denmark. Kirstine Hardam was delayed due to the competition authority dragging out in time, and both we and the seller decided that. Let's take a step back and focus on other things. So for us, it is important to be clear. It almost never happens. These discontinued processes. But you should never continue something that you don't feel is 100% right. So we have now focused on our strong pipeline and are replacing that with another company. So all in all, a very good operational performance in the M&A team and the pipeline; with good visibility, down to the left, we are showing what we talked about. When we look at a full year in M&A. It is important for us, of course, to deliver over 15% annual growth on EBITA, which we have done for many years. And the biggest part of that is using our cash to buy new companies. And that usually is 10% to 12% of the annual growth. So for us now when closing Q2, we are happy to see that we are a bit ahead of that acquisition curve. So for this year, we have good visibility. So, continuing to do acquisitions during the fall is what we can look forward to as we integrate our latest acquisitions. Um,Ms. RMS Medical Devices that we closed in April. It is a fast-growing medical device distributor serving hospitals and healthcare institutions across the Benelux. They have different areas of expertise, as do all the companies that we buy. A little bit of artificial intelligence comes in here as well. It is, you know, more and more companies use that to help customers in a good way. They have 40 years of experience in the Belgian market. And they have roughly 170 million in annual sales with 25 employees. And we expect them to contribute positively to our EBITA margin as well. So a good acquisition. All right. Coming to an end. To summarize this, then, this quarter was a good, middle-of-the-road, stable quarter. So, of course, the 24% total growth, out of which 6% is organic EBITA growth, is something we are really proud of in a market that is growing by 3% to 4%. This shows both that we can grow faster than the market and also leverage the group scale to achieve faster growth on the bottom line, reaching a 10% EBITA margin, which is our target. So we continue to deliver a good and robust cash flow. The M&A process is according to plan. So with that, I think we can close this presentation and go into Q&A.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Gustav Burnell from Nordea. Please go ahead.
Yes. Good morning. It is Gustav from Nordea. I thought maybe just to start off with North, if we can just give a bit more color there. On the strong organic growth of 10% year-over-year. If there are any one-off related larger orders from defense and so forth, or if it is just broad-based, or more related to a more easy base effect from last year.
Yeah. I can say a word or two about that. Gustav. I think, to answer your first part, there are no big lumpy one-off orders similar to what we had back in 2024. I would also say, as Johan mentioned, we would continue to push you to think about the rolling 12 months, and not get too hung up on one individual quarter. So, 10% is obviously a strong figure, but I don't think we should suddenly conclude that there's anything particularly special happening in North. The region is doing well. They are performing nicely operationally. They are doing good things. We look forward to getting the new distribution center up and running. But this is more of a steady, solid, strong base performance from the region rather than anything that indicates anything other than that.
Okay. That is very clear, and on the earnout payments you comment on here for 2027 of 150 million, is it possible to elaborate a bit more on how much larger they can potentially be and if they will also be paid out in Q2?
That is a good question. Yes, the vast majority of them will be paid out in Q2. I anticipate they will all be paid out in Q2. But things can happen. But yes, Q2 is typically the quarter we pay them out. The reason for that is we wait for the fully audited and signed-off annual reports from the end of the previous year. And that usually takes a couple of months and that becomes available in Q2. And then we pay the earnouts exactly as we have done in 2026. And the earnout payments that will be paid in 2027 are for companies that come to the end of their earnout in December 2026. And typically, those companies are companies that will have had an earnout period that has run through 2024, 2025, and 2026. So they will have run for three years up to that point. And then the earnout is paid. Obviously, 2024 is done. 25 is done. 2026, we are halfway into it. So if you think about it, we are already about 75% to 80% of the way into the final calculation of that earnout period. So the likelihood that that figure would change dramatically is very small, because the vast majority of that earnout calculation is already finalized, if that makes any sense. I feel I made that more complicated than it was supposed to be, but I hope that makes sense now.
But that's very clear. If you cannot state a full figure, I take that for sure.
No, but I think what I'm trying to say is when we say 150 million, it might be 10% higher or 10% lower, depending on how the last six months of the three-year earnout period develops. But it is not going to suddenly jump to 300 million. Partly because there isn't time for those companies to earn sufficient extra earnings to justify that. And also the way we have gradually evolved and developed the earnout model over recent years is we have actually established a more firm ceiling on how much the maximum earnout payment can be. So, the earnouts that we paid out this year had a more generous ceiling than the future earnouts have and will have. So, you can be confident that that 150 million, yes, it might move a little bit up and down, but it is not something that will move dramatically.
That is very clear. Thank you, Thomas. And then just the last question here; I know you have discussed the warehouse here in Gothenburg, but can you just remind us, is there anything we should be aware of in terms of which quarter will be a large move for you? Where might you anticipate an effect on volumes or anything else? Yeah. Just that might hamper earnings or sales.
Got it. Yes. No, I can say I think our philosophy with this and the quality of the team that we have down there means that we don't expect any operational impact in terms of volumes. Our customers will not see the effect of this transfer. And we are confident that we have backup plans and redundancies in place to ensure that there won't be a short-term influence. The plan is to continue to gradually ramp up the operational activities through Q3 and Q4 this year. And effectively, we will be fully operational in the first half of 2027. And then obviously, there will be some minor teething issues that we need to work through, so we expect the full benefits of the 50 to 60 million SEK a year that we expect to save. Those full benefits will not start to be seen in the P&L until H2 2027.
That is clear. But will there be any dual costs or anything like that?
Sorry. Yes, to address the second half of your question. Yes. We anticipate a very low single-digit million SEK impact in terms of double-manning, and the largest chunk of these double-manning costs will likely be seen in Q4 this year. There will be perhaps a little bit in Q3 and a little bit in Q1. But we expect low tens of millions of SEK in double manning costs at the back end of this year. There will also be a temporary effect on working capital, perhaps somewhere between 50 and 100 million of additional working capital that we will have for double inventory during that same time period, primarily concentrated at the back end of this year into the first part of next year.
I hope that's clear. Low single digits. Is that for Q3? Q1 and Q4 respectively, or?
No, no. It is a combined total.
Combined. Okay. That's clear. Thank you very much for taking my questions.
No worries. Thank you.
The next question comes from Jakob Lemke from SEB. Please go ahead.
Yes. Hi and good morning. My first question is on North, where the EBITA margin is down here for the second consecutive quarter, despite what I believe is some positive impact from M&A. So, could you elaborate a bit on what is behind that, please.
Yeah. I can in a way give you the same answer as I. I just gave to Gustav Jakob. I think there will always be small fluctuations up and down when I look at the margin in North. The rolling 12-month margin in December 2025 was running at 13%. The last 12-month figure when we looked in Q1 was running at 13.1%. The figure now is 13.5%. So, from our perspective, margins are stable in North. I wouldn't read too much into what looks like a sequential drop. As I say, we are confident that margins are running at a stable level above 13%.
Okay. And looking ahead to Q3, it seems like the margin is usually a bit lower in Q3. Is it possible to guide how much that sort of sequential drop usually is?
Again, I would guide you to look at the rolling 12-month margins. I think you are right. Q3 historically and currently tends to be our weakest quarter, the smallest quarter overall. But I would continue to look at the rolling 12-month figure, and we expect that to continue at the 13% plus level in Region North. There is nothing going on. That means that there should not be a dramatic change to that.
Okay. Then on the West, the organic growth is a bit lower than we have been used to, but I think the organic EBITA growth still looks quite good. So if you can elaborate on what is happening in West as well.
Yeah. I will provide a similar answer. I would not read too much into that. I think you need to always look at this business on a rolling 12-month basis. We did have particularly strong organic revenue growth in West going back last year, and clearly, anything above 10% organic revenue growth was not going to be maintained in a market that is only growing at 3%. In the quarter, as you say, it is a little bit lower. The half-year figure is running at 4%. But we are delivering strong leverage to the EBITA growth. Region West continues to perform well. We expect the organic revenue growth in region West to continue to be stronger than the market, perhaps up to twice the rate of the market. Like everywhere else. There is no significant shift in the underlying steady, solid, strong performance that we have in region West.
But if I may follow up then, is the momentum in the home care business in West still strong or is that slowing down a bit?
No.
Is there something else that is a bit slow? It is a meaningful sequential drop, I would say, in the organic growth.
No, I think we would not say that we see any particular slowdown in the opportunities in the home care business. We continue to build strength and scale there. So we have no concerns. I understand when you look quarter on quarter mathematically, you see what you perhaps could conclude is a slowdown. But I do not think that is a fundamental change in the market dynamics. It is important to understand that this region is, you know, the home care is a very significant and important part and has driven the strong growth in West. But that's not the only thing that's going on in the region. So I would not jump to the conclusion that somehow the opportunity in home care has suddenly stopped.
Okay, then I have a question also on M&A. I think that, looking at the deals you have done. The M&A growth will come down a bit in Q3, but it will likely still be at your target level, though it will decrease further in Q4 and likely fall below the target level you want to maintain. So, just based on what you are seeing now in the pipeline, how confident are you that you will be able to sustain that sort of 10% to 12% M&A growth also for Q4?
I mean, when we look at the number of deals in the pipeline. We have more than we can digest, so to speak. We have hundreds of deals that we look at and 10 to 20 deals in very concrete discussions. So the number of deals and the quality of the deals will not be an issue over the next two to three years, as we have no reason to believe that the pipeline will dry out. So the question is only how much money do we have to buy deals? Staying disciplined under 2.5 times Net Debt/EBITDA and with a high cash conversion and very low CAPEX, we know that the money will give us 10 to 12% growth on M&A. We have no reason to say that that will not continue for the foreseeable future. And then on top of that, we have the organic growth that we have seen. So, and then of course, it could be one quarter a little bit more, one quarter a little bit less. Now, I think technically we have done 57% of the annual target. But that is, you know, more a coincidence of when a deal closes and gets pushed into a certain quarter or not. So, when it comes to M&A, it is going to continue steadily. That is the least thing we are worried about. I would say.
Okay. That is all for me. Thank you.
Thank you.
The next question comes from Erik Castel from Danske Bank. Please go ahead.
Hi. Good morning, everyone. I first want to discuss a bit on the organic growth outlook for North specifically. There appear to be some pushes and pulls to my eyes as well. If I recall correctly, you had the Skåne logistics contracts that went in-house in May. First, was that something that you have seen in effect now through the second half of this quarter, or are they still mainly sourcing from you? And are you seeing any other regions going in-house and sort of changing the way they source? Secondly, on the Swedish stockpiling preparedness rules that are coming into effect in January, I believe almost 600 million has been allocated to spend funds on that already in 2026. Is that something that you are seeing positively on for H2, and then lastly, what is the pipeline of defense contracts that you may be seeing now if you have anything on that? I think all of that would be helpful.
Should I start?
Should we start?
I think, first of all, we should take a slight step back and remind ourselves that the group is large and diverse, with 19 countries and 70 companies. So obviously, Sweden is one of the larger units in the group. Individual contracts in an individual country and an individual company do not significantly impact the group as a whole. They make a relatively minor impact on the group as a whole. We continue to expect, believe, and see that the group as a whole will deliver organic EBITDA growth faster than the market. Maybe not quite twice the rate of the market, but definitely faster than the market. We will continue to add margin expansion on top of that, which means that we should be seeing EBITA growth somewhere in that 5%, 6%, 7%, 8% range. Sometimes it will be a bit more, sometimes it will be a bit less. Sometimes one region will contribute a bit more. Sometimes one region will contribute a bit less. But big picture. That is what we expect to see. And there will be very few occasions where individual companies or individual contracts significantly alter that fundamental long-term underlying trajectory. So, I think we should keep that in mind. In terms of your very specific questions, Eric. Yes, the developments with Scorner have been well known. They have been part of our plans. Actually, that is not what I was going to say. That is not a huge part of our business. Even though the volumes are relatively large, it is primarily a flow-through operation. So it does not have a huge effect on our financial statements. Actually, we are continuing to service that contract as well. Scorner is not yet ready to take that fully in-house as far as I understand it. So that shouldn't have any meaningful effect on Q3 or Q4. And even if that business eventually moves somewhere else, it won't have a big effect either because of the scale I was just describing. In terms of defense, I think there is a huge amount of defense and preparedness thinking and work going on in multiple countries, and multiple companies around the group are involved in lots of interesting discussions. To say that we would expect specifically the Swedish announcement that you mentioned to have some sort of meaningful bump in the figures. Again, I don't think you should suddenly add in a big extra chunk on top of the normal flow in the North or in the Swedish figures.
Maybe for me to add to the general trend, I mean, what Vårgårda made a decision a couple of years ago to take it in-house. That is against the overall trend in Europe; what we see is that regions, municipalities, and healthcare providers are struggling to manage 5,000 plus products with clean room requirements and with very small parcels delivered to many different addresses. So they usually come to us so we can help them with that. We have a lot of good initiatives moving towards that trend held in southeast Norway, where we have departmental PACs helping hospitals to get the right products at the right department in a quite complex system. So the trend is definitely going that way. So this is not something that we are afraid of at all. Rather, as the market leader in Europe with a very strong logistic backbone, we can support this region to do it more efficiently, especially now when they need prepared stock. But you are requested quite often to support regions and municipalities with that across Europe.
Okay, great. Thank you for a long answer and good one as well. I only have one more question regarding the acquired companies' margins. If I have calculated correctly, they are still tracking quite a bit above what you have discussed. I get to almost 17% in margins incrementally now. I think I asked a similar question at Q1 as well. And you said they are above 10%, but I probably shouldn't expect them to keep tracking at this margin level for the full year. So I sort of repeat that question from Q1. Are you then expecting some sort of drop in those acquired companies' margins for H2? Or can they now continue to trend on this level?
I have to be honest, Eric, I don't fully recognize that calculation. Maybe you want to send me a little Excel file afterwards and we can discuss it a bit. You know, these companies definitely are margin enhancing to the group. I think we half-joked about it before in our sort of coded language. If we talk about margin enhancing, you can guess that it's above 10%. But if we were actually buying businesses that were adding 17%, as you mentioned, we would probably talk about strongly margin-enhancing or something like that. So, these companies are not strongly margin enhancing, but they are margin enhancing. So, yeah, I think that we would have to dive into that a little bit because I certainly don't recognize that figure.
Okay. Yeah, it might as well be my math as well.
No, no.
You are saying that.
There is none.
There is no downside to where margins are tracking now.
I suppose, in terms of the underlying thought in your question, is there a fear that there will be some kind of negative bounce back to come from what these businesses contribute? Absolutely not. No. They have come in and are performing nicely. They are performing solidly. We expect them to continue to do that. So there is no step change in what they will contribute to the group. No.
Okay. Perfect. That's all for me. Thank you.
The next question comes from Albin Nordmark from SB1 Markets. Please go ahead.
Good morning Johan and Thomas. Hope you can hear me. I have a question on the margin bridges. So gross margin was up around 110 basis points year-over-year to 42%. And adjusted EBIT margin was up 52 basis points. What is driving the gross margin, is it purchasing credits in terms of pricing? And then what is the offset below the gross profit line? Yeah, thanks.
Yeah, I.
I can take that. I think you half answered it in the question itself. But the biggest element that contributes to this picture is mix. So the businesses that we buy and have bought over the last few years have come in with higher gross margins than the average of the organic group. But in terms of the way we lay out our P&L, they have much higher costs as well. They tend to be more equipment heavy. They tend to be more service-oriented and have a higher degree of, for example, sales or technical staff versus the consumable businesses. So the structure, the shape of the P&L of the businesses that we've bought, but often also some of the businesses and the new business areas we've developed into, is different from the historic core distribution P&L. And that difference is that they come in with much higher gross margins. But net-net, they only have slightly higher EBIT margins, and that gradually shifts and distorts the P&L over time. Having said that, of course, we continue to work with our COGS, we continue to work with our pricing, and we continue to work with our relationships with the OEMs and our customers as well. So we are getting true organic benefits to margin at the gross margin level as well. But perhaps the larger impact is on mix effect.
And nothing related to own brands.
No.
No, I think private label is an interesting topic. It is one that we have touched on a little bit before. It's around 10% of our current revenues. But for us, own label is very much a patchwork of different offerings that we have that have come with the M&A that we've done through the years. We definitely see a systemic opportunity for own label as the industry consolidates and as we go into the future. But I think that's more of an opportunity for the future than something that we are driving particularly hard in the short term.
That's clear. And then just a quick one on tax. It was 21% here in the quarter. I believe you provided guidance of 22% to 23%. So in Q1. So is there anything; should we just model in the low end here or is there anything to add?
No, I think there are always sort of small fluctuations there as well, regarding particular companies or particular situations. But if I look at my own Excel, I have 22% to 23% in it. If you want to follow my modeling, I would stick at the more cautious end of the range rather than suddenly reading something into the fact that it was a tiny bit lower in Q2.
Okay. That is good. That is all for me as well. Thanks.
Thanks.
The next question comes from Charles Weston from RBC. Please go ahead.
Hello. Thanks for taking my questions. Both relate to the UK, so I'll ask them together if that's okay. First of all, could you characterize the demand environment in the UK as part of West in Q2, particularly as it relates to capital versus consumables? I ask this because a peer flagged strong orders, but customers are deferring delivery. So we are just trying to understand whether that is a shared dynamic or specific to their channel. And the second question relates to the new value-based procurement guidance in the NHS in June. Just wondering if that has affected purchasing timelines for your UK customers or perhaps it is too early to see that yet. Thank you.
Yes, I can try and take that one. I think typically, in a way, I would go back to one of the answers I gave earlier on in terms of the scope, the scale, and the diversity of the group. So we are always a bit reluctant to blame or praise any individual company or country that does anything out of the ordinary. But in terms of the UK, I am also conscious there is a lot of noise and commentary floating around that we do not have a massive business in the UK. I think that's also important to state. So, HSL, the platform that we bought in West, has good operations in Ireland and Northern Ireland. We have subsequently added a couple of smaller bolt-ons in the UK itself. So, for us, the UK is not a large market at the moment, but it's one that is interesting and we'd like to get into more in the future. If I come to your specific point in terms of delays and procurement orders, I guess we can say that we have heard a little bit of noise around the topic. But it hasn't had any long-term, severe, or meaningful impact. I think we just take that as part of the normal cycle. Sometimes things are a bit slower, sometimes they come back. But fundamentally, money gets spent on healthcare. Johan often talks about the hierarchy of government needs. And, you know, governments will continue to spend money in healthcare on patients, on capital goods. So if it's a little bit later, or comes one quarter later or two quarters later, it's okay; it will come, and the money will be spent. That is our general view, general philosophy, and it has been proved out over time. In terms of the very specific new procurement rules that you mentioned regarding the UK, I am not in a position to comment on that. I think it's too early to say, and I certainly don't have any particular insight into any impact that would have. But again, I would put it back into the box of the answer that I just gave. I think money will be spent eventually.
I will quote you on that. That is a good one.
One. Yeah. Please don't, please don't.
The next question comes from Jakub Lemke from SEB. Please go ahead.
It is a short one. The other operating income in the quarter. That is 24 million. Is that due to currency effects or what is that?
No, that actually is the point. There is a very small contribution in there from the sale of a building that came with an acquisition. Jakub, let me get back to you on that before I give you a half-baked answer to double-check that.
Okay. If there is one of the effects in that which has been adjusted for in adjusted EBITA.
No, there is no major one-off effect. The sale of the building netted us a profit of just under 2 million SEK. So there was a tiny positive effect there. But there is no significant EBITDA effect associated with that.
Okay. Fair enough. Thank you.
There are no more questions at this time. So, I hand the conference back to the speakers for any closing comments.
All right. Thank you for the good questions and for taking the time once again. I wish you a very nice summer and see you in Q3. Goodbye.



















